Kelly CRISPR & Gene Editing Technology ETF Rating $7.38 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Ratings Stock AnalysisChartOptions ChainRatingsTrends Kelly CRISPR & Gene Editing Technology ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XDNA Aggregate RatingModerate Buy 2.76Holdings in XDNA have an aggregate rating of Moderate Buy based on 303 analyst ratings issued in the past year covering 20 companies (91.3% of the portfolio).XDNA Aggregate Price Target$7.38High Prediction$7.38Average Prediction$7.38Low Prediction$7.38Holdings in XDNA have an aggregate price target of $7.38 and a range of $7.38 to $7.38 covering 20 companies (91.3% of the portfolio).XDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy11 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Kelly CRISPR & Gene Editing Technology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 20 XDNA Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.05%NTLAIntellia Therapeutics$12.17-0.7%4.3832 of 5 stars2.72$48.71 300.2%18News CoverageGap Up10.70%TMOThermo Fisher Scientific$532.55-1.0%4.7267 of 5 stars2.82$656.86 23.3%22Dividend IncreaseAnalyst RevisionPositive News9.57%BEAMBeam Therapeutics$30.43-8.2%3.125 of 5 stars3.00$47.67 56.6%12Gap Up8.64%CRSPCRISPR Therapeutics$47.91-5.0%3.157 of 5 stars2.50$74.40 55.3%22Analyst ForecastInsider TradeOptions VolumeAnalyst Revision6.78%CRBUCaribou Biosciences$1.31-7.1%3.1284 of 5 stars3.00$10.33 688.8%55.63%VERVVerve Therapeutics$7.28-7.0%2.9255 of 5 stars3.00$25.75 253.7%5Upcoming EarningsAnalyst Forecast5.16%SGMOSangamo Therapeutics$1.07-4.5%1.8713 of 5 stars2.67$5.17 382.9%64.73%PRMEPrime Medicine$2.96-5.4%2.5256 of 5 stars3.10$13.13 343.4%10News Coverage4.37%ABBVAbbVie$202.03+0.6%4.641 of 5 stars2.88$208.35 3.1%24Dividend AnnouncementAnalyst RevisionPositive News4.13%EDITEditas Medicine$1.92-7.0%4.6356 of 5 stars2.07$7.00 265.5%14Gap Up4.10%ALLOAllogene Therapeutics$2.17-4.0%2.8306 of 5 stars2.90$9.73 348.5%10Gap Up2.96%DTILPrecision BioSciences$5.91+0.3%4.3251 of 5 stars3.00$37.67 537.3%3Analyst ForecastNews Coverage2.87%TSVT2seventy bio$2.61-2.6%2.1794 of 5 stars2.50$7.20 175.9%6Analyst ForecastNews CoveragePositive News2.40%AAgilent Technologies$135.33-1.1%4.0867 of 5 stars2.50$144.38 6.7%14Upcoming EarningsDividend AnnouncementNews CoveragePositive News2.10%BMYBristol-Myers Squibb$55.85+0.1%4.5826 of 5 stars2.30$57.86 3.6%20Analyst RevisionPositive News2.00%ILMNIllumina$94.20-3.1%4.7705 of 5 stars2.62$159.45 69.3%211.53%VRTXVertex Pharmaceuticals$484.24+0.8%4.0991 of 5 stars2.65$506.70 4.6%26Analyst DowngradeInsider TradeAnalyst RevisionPositive News1.29%REGNRegeneron Pharmaceuticals$700.33+0.6%4.7594 of 5 stars2.76$973.13 39.0%25Dividend Announcement0.69%QGENQiagen$39.52+2.5%4.4256 of 5 stars2.30$47.71 20.7%10Analyst Downgrade0.57%BIIBBiogen$140.64+2.6%4.7368 of 5 stars2.43$213.33 51.7%30Analyst Forecast This page (NASDAQ:XDNA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Kelly CRISPR & Gene Editing Technology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
